These vaccine candidates for Campylobacter hepaticus in chickens offer a potential approach to controlling Spotty Liver Disease, an acute and economically damaging condition affecting commercial laying hens, resulting in significant economic losses in the egg industry. Once contracted, Spotty Liver Disease can lead to 15% flock mortality and a 35% reduction in egg production. Available means of managing the infection rely exclusively on antibiotics. This route has become increasingly ineffective due to the growing resistance to antibiotics and incompatibility with the expanding market for antibiotic-free eggs. The U.S. egg industry, valued at over $21 billion in 2024, is rapidly expanding to meet the growing demand for cage-free and antibiotic-free eggs. However, with no commercial vaccines available and the industry shift toward cage-free and antibiotic-free production, a growing need for a sustainable, non-antibiotic solution to control Spotty Liver Disease demands a solution.
Researchers at the University of Florida have developed a targeted vaccine approach that combines antigen discovery through page display and reverse vaccinology with a genetically engineered avian E. coli vector system, enabling effective delivery of protective C. hepaticus antigens to laying hens. Unlike traditional antibiotic treatments, this approach offers a sustainable and practical solution for managing flock health. The development of an effective vaccine offers poultry producers a sustainable alternative to antibiotics, expanding market opportunities and supporting long-term disease control without the risk of antibiotic resistance.
A vaccine-based solution for preventing Spotty Liver Disease in laying hens, ensuring flock health and sustained egg production, and providing a path to antibiotic-free poultry farming
This vaccine platform integrates advanced antigen discovery, genetic engineering, and scalable delivery mechanisms to immunize poultry against Spotty Liver Disease caused by Campylobacter hepaticus. The technology targets key antigens, including flagellar proteins and major outer membrane proteins, identified using phage display and reverse vaccinology. An avian E. coli-vectored system delivers these antigens, ensuring effective immunization in laying hens. Vaccination can be performed orally, via drinking water, or by topical spray, enabling mucosal and systemic immune responses in laying hens. The platform supports administration from the day of hatch through adulthood, with repeat dosing as needed for long-lived birds. The vaccines are designed to reduce mortality, maintain egg production, and support antibiotic-free farming practices. The technology also provides cross-protection against E. coli-induced egg peritonitis and other forms of colibacillosis, thanks to its dual-action vector system. All components are formulated for stability, ease of use, and compatibility with large-scale, antibiotic-free commercial poultry operations.
